Anti-CD39L3 Antibodies for Non-Invasive Beta Cell Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective, non-invasive means to quantify beta cell mass and isolate islet β cells in humans, hindering diabetes diagnosis and treatment, particularly for type 1 and type 2 diabetes, as well as islet transplantation efficacy.
Innovation Solution
The use of anti-CD39L3 antibodies, nucleic acid probes, and labeled small molecules to detect and isolate islet β cells through non-invasive imaging and invasive methods, enabling assessment of β cell mass and transplantation success.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If morphometric analysis of histological sections is used to quantify pancreatic islet mass, then measurement precision is improved, but ease of operation deteriorates due to requiring pancreas removal
Solution Approach 1:
The patent replaces invasive mechanical/surgical procedures (pancreas removal and histological sectioning) with non-invasive molecular imaging techniques. Specifically, it uses radiolabeled or fluorescent antibodies that bind to beta cell surface antigens (such as insulin, glucagon, or other islet-specific markers), allowing quantification of beta cell mass through external imaging modalities like PET, SPECT, or fluorescence imaging without surgical intervention.
Solution Approach 2:
The patent introduces intermediary molecules (radiolabeled antibodies, fluorescent probes, or small molecules) that specifically bind to beta cell surface antigens. These intermediaries serve as mediators between the imaging system and the beta cells, enabling indirect but non-invasive detection and quantification of beta cell mass while maintaining measurement precision.
2Ease of operation
If cell surface antibodies targeting human beta cells are developed for non-invasive detection, then ease of operation is improved, but device complexity increases due to requiring new antibody targets and methods
Solution Approach 1:
The patent employs universal detection platforms (PET imaging, SPECT imaging, fluorescence imaging) that can detect multiple different radiolabeled or fluorescently labeled antibodies and probes. This multi-functionality allows the same imaging infrastructure to detect various beta cell markers and perform different types of measurements, reducing the need for separate complex systems for each detection method.
Solution Approach 2:
The patent utilizes parameter changes in the detection approach by switching between different imaging modalities (PET, SPECT, fluorescence) and different molecular targets (various beta cell surface antigens). This flexibility allows optimization of detection sensitivity and specificity for different clinical scenarios without requiring fundamentally new and complex detection systems.
3Measurement precision
If invasive methods are used to assess beta cell mass over time, then measurement precision is improved, but loss of time increases due to repeated surgical procedures
Solution Approach 1:
The patent enables continuous or repeated non-invasive monitoring of beta cell mass over time using the same antibody-based imaging approach. Researchers can administer the same or different radiolabeled antibodies at multiple time points and perform imaging studies without surgical intervention, allowing longitudinal assessment of beta cell mass dynamics, disease progression, and treatment effects in the same subjects.
Solution Approach 2:
The patent allows for preliminary non-invasive assessment of beta cell mass and characterization of beta cell surface antigen expression before committing to invasive procedures. This preliminary information can guide study design, patient selection, and treatment planning, potentially reducing the need for repeated invasive procedures and saving time in the overall research or clinical workflow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables non-invasive detection and isolation of islet β cells, facilitating early diabetes diagnosis, treatment, and evaluation of β cell transplantation, improving understanding and management of diabetes.
Implementation Method 1
administering to the subject an anti-CD39L3 antibody... detecting β-cells using more invasive methods comprising a) administering to the subject an anti-CD39L3 antibody
Implementation Method 2
administering to the subject an anti-CD39L3 antibody, nucleic acid probes specific for CD39, or labeled small molecules that target CD39
Implementation Method 3
separating the cells expressing CD39L3 using fluorescence activated cell sorting (FACS) or magnetic bead separation to detect cells bound by the CD39L3 antibody
Implementation Method 4
separating the cells expressing CD39L3 using fluorescence activated cell sorting (FACS) or magnetic bead separation to detect cells bound by the CD39L3 antibody
Data Source
AI summary
In spite of significant efforts to identify β-cell-specific markers for β-cell imaging and purification, progress has been limited. Herein is disclosed a novel biomarker of human pancreatic β-cells, CD39L3 (also known as ectonucleoside triphosphate diphosphohydrolase-3 (NTPDase3)). Disclosed are compositions and methods for purifying and imaging β-cell using anti-CD39L3 antibodies.